GlassScriptPhysician profile
Elizabeth Rios
NPI 1417790700
$703.89
in general payments reported to CMS, 2019-2025
16 companies · $535 in 2025
The $535 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $169 · 2025: $535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $704.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $703.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $122.73 | 2024-2025 | Krystexxa, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $92.01 | 2024-2025 | |
| Exact Sciences Corporation | $81.49 | 2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $77.18 | 2025 | Auvelity, Symbravo |
| Novo Nordisk INC | $71.93 | 2025 | Ozempic, Rybelsus |
| Intuitive Surgical, INC. | $33.97 | 2025 | |
| Lilly USA, LLC | $33.76 | 2024 | Zepbound, Mounjaro |
| Novartis Pharmaceuticals Corporation | $27.56 | 2025 | |
| Dexcom, INC. | $24.47 | 2025 | Dexcom G6 Transmitter |
| Corium, LLC | $23.45 | 2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $21.23 | 2024 | Trintellix |
| Merck Sharp & Dohme LLC | $20.67 | 2024 | Gardasil, Gardasil 9, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $20.52 | 2025 | Farxiga |
| Seqirus USA INC | $18.62 | 2025 | Fluad, Flucelvax |
| Sumitomo Pharma America, INC. | $18.06 | 2024 | Gemtesa |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $16.24 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Rios listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.